Drug intelligence / Profile preview

ProLectin-A

Development stage: Preclinical
Lead developer: BioXyTran
Administration: Intravenous

Overview

ProLectin-A is an investigational intravenous galectin antagonist being developed by BioXyTran for the treatment of acute respiratory distress syndrome (ARDS) secondary to COVID-19. It is a carbohydrate-based therapeutic designed to target galectins, specifically by blocking the galectin fold on the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. This mechanism is intended to inhibit viral adhesion and entry while simultaneously modulating the immune response to reduce macrophage trafficking and the subsequent cytokine storm, thereby restoring immune homeostasis in severe cases.

Targets

S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)Galectin (Galectin family)

Beyond the preview

Go deeper on ProLectin-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProLectin-A.

Explore the full profile